Salta al contenuto principale
Passa alla visualizzazione normale.

VITO CHIANTERA

Morbidity after pelvic exenteration for gynecological malignancies : A retrospective multicentric study of 230 patients

  • Autori: Chiantera, V.; Rossi, M.; De Iaco, P.; Koehler, C.; Marnitz, S.; Fagotti, A.; Fanfani, F.; Parazzini, F.; Schiavina, R.; Scambia, G.; Schneider, A.; Vercellino, G.
  • Anno di pubblicazione: 2014
  • Tipologia: Articolo in rivista (Articolo in rivista)
  • OA Link: http://hdl.handle.net/10447/179442

Abstract

Objective: Our study purposewas to evaluatemorbidity and postoperative mortality in patients who underwent pelvic exenteration (PE) for primary or recurrent gynecological malignancies. Methods: We identified 230 patients who underwent PE, referred to the gynecological oncology units of 4 institutions: Charitè University in Berlin, Friedrich-Schiller University in Jena, S. Orsola-Malpighi University in Bologna, and Catholic University in Rome and in Campobasso. Results: The median age was 55 years. The tumor site was the cervix in 177 patients, the endometrium in 28 patients, the vulva in 16 patients, and the vagina in 9 patients. Sixty-eight anterior, 31 posterior, and 131 total PEs were performed in 116 women together with hysterectomy. A total of 82.6% of the patients required blood transfusion. The mean operative time was 446 (95-970) minutes, and the median hospitalization was 24 (7-210) days. We noted a major complication rate of 21.3% (n = 49). We registered 7 erioperative deaths (3%) calculated within 30 days. The operation was performed within clear margins in 166 patients (72.2%). The overall mortality rate depending on tumor site at the end of the study was 75%for vulvar cancer, 57.6%for cervical cancer, 55.6%for vaginal cancer, and 53.6% for endometrial cancer. Conclusions: Although an important effort for surgeons and for patients, PE remains a therapeutic option with an acceptable complication rate and postoperative mortality. A strict selection of patients is mandatory to reach adequate surgical and oncologic outcomes. © 2013 by IGCS and ESGO.